ICON Forms Strategic Alliance With Boston Clinical Research Institute
11 Maio 2011 - 5:00AM
Business Wire
ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced a
strategic alliance with Boston Clinical Research Institute (BCRI),
an Academic Research Organisation based in Boston, Massachusetts.
The alliance will combine BCRI’s respected leadership in clinical
strategy, study planning and academic relationships with ICON’s
experience in the execution of global clinical trials.
BCRI provides scientific consultancy in study design using
expert practising clinicians and key opinion leaders from premier
medical institutions, and also maintains a network of global
investigators in all of the medical specialties and subspecialties.
BCRI also provides academic leadership for Steering Committees,
Advisory Panel Participation, Endpoint Committees, Core Laboratory
Services, and Data Safety and Monitoring Boards.
“We are extremely pleased to announce the partnership with
ICON,” commented Dr. Michael Gibson, Founder and Senior Consultant
at BCRI. “We believe that the future of clinical research is
collaboration between the ARO and the CRO. ICON clearly recognises
the incremental benefits of collaboration with the thought leaders
in the medical community to optimise study planning, execution, and
credibility.”
Commenting on the alliance, Peter Gray, CEO at ICON plc, said,
“We are delighted that Dr. Gibson and BCRI have aligned with ICON.
The relationship provides ICON and its clients access to a breadth
of expertise in the key opinion leader community and to
investigators worldwide, including national and international
leaders. Anticipated benefits include enhanced planning, design,
site selection and enrolment performance.”
Jonathan Goldman MD FACC, Executive Vice President of Strategic
Development at ICON Clinical Research, commented, “The relationship
between BCRI and ICON further enhances our scientific expertise and
access to investigators. We look forward to building on these
relationships to enhance our feasibility services and to optimise
the investment of our clients as a result of accelerated
enrolment.”
Notes to Editors
About Dr. C. Michael Gibson, M.S.,M.D., F.A.C.C.
Dr. C. Michael Gibson MS, MD, FACC, is an Associate Professor of
Medicine at Harvard Medical School and is a consulting Professor at
the Duke School of Medicine. Gibson has led his own ARO for twenty
years and has functioned as the principal investigator of numerous
Phase I-IV clinical trials of up to 15,000 patients and as a senior
investigator in the TIMI Study Group
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has almost 8,000 employees, operating from 77 locations in 38
countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024